Green Alpha Advisors LLC Sells 159 Shares of BioNTech SE (NASDAQ:BNTX)

Green Alpha Advisors LLC trimmed its stake in BioNTech SE (NASDAQ:BNTXFree Report) by 4.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,837 shares of the company’s stock after selling 159 shares during the period. Green Alpha Advisors LLC’s holdings in BioNTech were worth $456,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Harding Loevner LP bought a new position in shares of BioNTech in the fourth quarter valued at approximately $410,984,000. Candriam S.C.A. grew its stake in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after acquiring an additional 341,311 shares during the period. SG Americas Securities LLC lifted its position in BioNTech by 610.5% during the 1st quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock worth $6,471,000 after acquiring an additional 60,270 shares during the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of BioNTech by 51.3% in the first quarter. Acadian Asset Management LLC now owns 111,398 shares of the company’s stock valued at $10,275,000 after purchasing an additional 37,792 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BNTX has been the subject of several research analyst reports. JPMorgan Chase & Co. raised BioNTech from an “underweight” rating to a “neutral” rating and boosted their price objective for the stock from $91.00 to $125.00 in a research report on Monday, September 16th. Deutsche Bank Aktiengesellschaft upped their price target on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and boosted their target price for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Finally, HC Wainwright raised their price target on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.92.

Get Our Latest Stock Analysis on BioNTech

BioNTech Price Performance

BioNTech stock traded down $1.13 during mid-day trading on Monday, hitting $121.55. 901,609 shares of the company were exchanged, compared to its average volume of 796,041. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $98.08 and a 200 day moving average of $92.61. The company has a market capitalization of $28.90 billion, a PE ratio of 243.10 and a beta of 0.24.

BioNTech (NASDAQ:BNTXGet Free Report) last announced its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company’s revenue for the quarter was down 23.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.86) EPS. As a group, sell-side analysts expect that BioNTech SE will post -2.87 earnings per share for the current year.

BioNTech Profile

(Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

See Also

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTXFree Report).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.